| ObjectiveTo clear whether Shuganjieyu Capsule on patients with primary hypertension,insomnia,stagnation of liver qi can improve sleep,bad mood conditioning effect.To clear whether on the basis of the traditional antihypertensive drugs(amlodipine combined with valsartan)by the improvement of sleep can increase the effect of antihypertensive drugsMethodsTotally 224 patients with primary hypertension,insomnia,stagnation of liver qi at the same time with the sleep quality scale(Pittsburgh Sleep Quality Index,PSQI>7)in our hospital from Dec 2015 to Apr 2017 according to the degree of high blood pressure can be divided into grade 1 hypertension,level 2,level 3 hypertension were randomly divided into the control group(who received Amlodipine besylate +valsartan orally)and the experimental group(who received Amlodipine besylate +valsartan combined with Shuganjieyu capsule orally),they were treated for 12 weeks.Blood pressure levels,Pittsburgh sleep quality(PSQI)score,anxiety self-assessment scale(SAS)score,depression self rating scale(SDS)score changes were compared before treatment,4 weeks and 12weeks after treatment between the two groups.ResultsAfter two follow-up visits,there were 180 patients with primary hypertension with insomnia at the same time with the sleep quality scale(Pittsburgh Sleep Quality Index,PSQI>7)in the experiment.And the control group:the basic informations of the patients who with Primary hypertension of grade 1 have 30 patients,the basic informations of the patients who with Primary hypertension of grade 2 have 30 patients,he basic informations of the patients who with Primary hypertension of grade 3,have 30 patients;the experimental group:the basic informations of the patients who with Primary hypertension of grade 1 have 30 patients,the basic informations of the patients who with Primary hypertension of grade 2 have 30 patients,he basic informations of the patients who with Primary hypertension of grade 3,have 30 patients.1.Before treatment,there was no statistically significant difference in systolic blood pressure(SBP)and diastolic blood pressure(DBP)and PSQI score,SAS score and SDS score in each blood pressure level 2 groups(P>0.05).2.The changes of the control group's ADASBP,ADADBP,PSQI,SAS,SDS and their efficacy were compared with the experimental group.(1)The control group:the basic informations of the patients who with Primary hypertension of grade 1,before treatment are:ADASBP(152.60 ± 4.72,mmHg),ADADBP(86.97±5.04,mmHg),PSQI(14.93±2.57),SAS(62.53±5.52),SDS(60.63 ±5.62);after 4 weeks treatment are:ADASBP(139.07±4.93,mmHg),ADADBP(79.77 ± 4.01,mmHg),PSQI(14.63 ± 2.88),SAS(62.50 ± 5.52),SDS(59.97±4.92);after12 weeks treatment are:ADASBP(128.87 ±3.56,mmHg),ADADBP(77.63±3.13,mmHg),PSQI(12.53±3.38),SAS(59.97±4.44),SDS(56.70 ±4.56);the basic informations of the patients who with Primary hypertension of grade 2,before treatment are:ADASBP(168.20 ±4.40,mmHg),ADADBP(94.53±4.85,mmHg),PSQI(14.93±2.08),SAS(60.53±5.24),SDS(61.33±5.87);after 4 weeks treatment are:ADASBP(137.43± 1.30,mmHg),ADADBP(82.77 ± 4.44,mmHg),PSQI(14.27±1.91),SAS(58.53 ± 5.26),SDS(61.03 ± 5.45);after12 weeks treatment are:ADASBP(128.67 ±3.26,mmHg),ADADBP(79.27±3.34,mnHg),PSQI(11.13±1.85),SAS(55.73±4.61),SDS(57.33±5.55);?the basic informations of the patients who with Primary hypertension of grade 3,before treatment are:ADASBP(183.93 ± 2.10,mmHg),ADADBP(104.60±6.05,mmHg),PSQI(14.87±1.78),SAS(59.83±4.00),SDS(59.20±4.05);after 4 weeks treatment are:ADASBP(148.23±1.99,mmHg),ADADBP(88.60±4.73,mmHg),PSQI(14.73± 1.55),SAS(59.30±3.75),SDS(58.20±4.27);after 12 weeks treatment are:ADASBP(130.17±3.64,mmHg),ADADBP(83.20±3.61,mmHg),PSQI(12.57± 1.45),SAS(56.03±3.50),SDS(55.83 ± 3.97).Compared with the before treatment,SBP and DBP in the control group were significantly reduced(P<0.05),PSQI score,SAS score and SDS score were significantly changed(P>0.05)after 12 weeks treatment but not after 4 weeks treatment.(2)the experimental group:the basic informations of the patients who with Primary hypertension of grade 1,before treatment are:ADASBP(152.23 ± 4.49,mmHg),ADADBP(86.53±4.64,mmHg),PSQI(15.27±2.35),SAS(62.53±5.52),SDS(62.97±5.26);after 4 weeks treatment are:ADASBP(131.77±4.85,mmHg),ADADBP(74.67 ± 3.48,mmHg),PSQI(8.53 ± 2.08),SAS(53.30±4.51),SDS(52.40±4.31);after12 weeks treatment are:ADASBP(123.40±3.15,mmHg),ADADBP(72.90±1.58,mmHg),PSQI(7.03±1.56),SAS(49.53±3.57),SDS(48.67 ±3.50);?the basic informations of the patients who with Primary hypertension of grade2,before treatment are:ADASBP(168.50 ± 4.09,mmHg),ADADBP(94.43±4.03,mmHg),PSQI(14.83± 1.91),SAS(60.33±5.01),SDS(61.07±5.22);after 4 weeks treatment are:ADASBP(131.70±4.29,mmHg),ADADBP(78.97±3.58,mmHg),PSQI(10.80±1.69),SAS(54.93±4.95),SDS(55.87±4.69);afterl2 weeks treatment are:ADASBP(123.77±3.49,mmHg),ADADBP(76.73±2.20,mmHg),PSQI(8.10±1.45),SAS(51.27±4.23),SDS(52.07 ±4.08);?the basic informations of the patients who with Primary hypertension of grade3,before treatment are:ADASBP(183.77±2.06,mmHg),ADADBP(103.10±4.66,mmHg),PSQI(14.90±2.06),SAS(60.07±4.12),SDS(59.10±4.67);after 4 weeks treatment are:ADASBP(143.63±2.98,mmHg),ADADBP(80.87±3.69,mmHg),PSQI(11.03±1.97),SAS(54.77±4.43),SDS(54.07±4.93);after 12 weeks treatment are:ADASBP(125.43±4.03,mmHg),ADADBP(77.93±2.74,mmHg),PSQI(8.47±1.68),SAS(51.33±4.19),SDS(51.13±4.64)?SBP,DBP,PSQI score,SAS score and SDS score were significantly reduced in the experimental group after 4 weeks and 12 weeks treatment(P<0.05).(3)Both SBP and DBP,PSQI score,SAS score and SDS score in the experimental group 4 weeks and 12 weeks after treatment were all lower than those in the control group(P<0.05).After 4 weeks treatment informations of the patients who with Primary hypertension of gradel the experimental group ADASBP were 5.3%lower than the control group,ADADBP were 5.7%lower than the control group,PSQI were 45.2%lower than the control group,SAS were 14.3%lower than the control group,SDS were 11.5%lower than the control group,after 12 weeks treatment informations of the patients who with Primary hypertension of gradel the experimental group ADASBP were 3.3%lower than the control group,ADADBP were 5.5%lower than the control group,PSQI were 39.0%lower than the control group,SAS were 15.8%lower than the control group,SDS were 13.1%lower than the control group.After 4 weeks treatment informations of the patients who with Primary hypertension of grade 2 the experimental group ADASBP were 3.6%lower than the control group,ADADBP were 4.2%lower than the control group,PSQI were 23.6%lower than the control group,SAS were 4.9%lower than the control group,SDS were 6.6%lower than the control group,after 12 weeks treatment informations of the patients who with Primary hypertension of gradel the experimental group ADASBP were 3.0%lower than the control group,ADADBP were 3.2%lower than the control group,PSQI were 20.0%lower than the control group,SAS were 6.6%lower than the control group,SDS were 8.1%lower than the control group.After 4 weeks treatment informations of the patients who with Primary hypertension of grade 3 the experimental group ADASBP were 2.7%lower than the control group,ADADBP were 7.7%lower than the control group,PSQI were 25.9%lower than the control group,SAS were 9.2%lower than the control group,SDS were 6.8%lower than the control group,after 12 weeks treatment informations of the patients who with Primary hypertension of grade 1 the experimental group ADASBP were 2.7%lower than the control group,ADADBP were 5.8%lower than the control group,PSQI were 26.8%lower than the control group,SAS were 8.3%lower than the control group,SDS were 8.4%lower than the control group.3.The adverse reactions of the control group and the experimental group.The control group:the basic informations of the patients who with Primary hypertension of grade 1,there was no one had the adverse reactions;the basic informations of the patients who with Primary hypertension of grade 2,there was one patient had a headache,so the incidence of adverse reactions was 3.33%;the basic informations of the patients who with Primary hypertension of grade 3,there was no one had the adverse reactions.The experimental group:the basic informations of the patients who with Primary hypertension of grade 1,there was no one had the adverse reactions;the basic informations of the patients who with Primary hypertension of grade 2,there was no one had the adverse reactions;the basic informations of the patients who with Primary hypertension of grade 3,there was one patient felt dizzy,so the incidence of adverse reactions was 3.33%.Conclusions1.Amlodipine besylate combined with valsartan has exact antihypertensive effect on the people who with primary hypertension,insomnia at the same time with the sleep quality scale(Pittsburgh Sleep Quality Index,PSQI>7).2.Amlodipine besylate combined with valsartan has exact effect on improving sleep on the people who with primary hypertension,insomnia at the same time with the sleep quality scale(Pittsburgh Sleep Quality Index,PSQI>7).3.Amlodipine besylate combined with valsartan has exact effect on improving anxiety,depression and other negative emotionson on the people who with primary hypertension,insomnia,stagnation of liver qi at the same time with the sleep quality scale(Pittsburgh Sleep Quality Index,PSQI>7).4.Amlodipine besylate combined with valsartan and Shuganjieyu Capsule has more exact antihypertensive effect on the people who with primary hypertension,insomnia,stagnation of liver at the same time with the sleep quality scale(Pittsburgh Sleep Quality Index,PSQI>7),and long-term use,more significant effect.5.Amlodipine besylate combined with valsartan and Shuganjieyu Capsule has more exact effect on improving sleep on the people who with primary hypertension,insomnia,stagnation of liver at the same time with the sleep quality scale(Pittsburgh Sleep Quality Index,PSQI>7),and long-term use,more significant effect.6.Amlodipine besylate combined with valsartan and Shuganjieyu Capsule has more exact effect on improving anxiety,depression and other negative emotionson on the people who with primary hypertension,insomnia,stagnation of liver at the same time with the sleep quality scale(Pittsburgh Sleep Quality Index,PSQI>7),and long-term use,more significant effect.7.Shuganjieyu capsule can improve the symptoms of insomnia,anxiety,depression and other negative emotions,relieve nerve endocrine system dysfunction,so as to improve the efficacy of antihypertensive drugs.This study may provide a new way of thinking for the clinical treatment of primary hypertension with insomnia.8.Amlodipine besylate combined with valsartan and Shuganjieyu Capsule has more exact effect on improving anxiety,depression and other negative emotionson on the people who with primary hypertension,insomnia,stagnation of liver at the same time with the sleep quality scale(Pittsburgh Sleep Quality Index,PSQI>7),... |
PDF Full Text Request